Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report by Shintaro Fujihara et al.
Fujihara et al. BMC Nephrology 2013, 14:141
http://www.biomedcentral.com/1471-2369/14/141CASE REPORT Open AccessLife-threatening gastrointestinal bleeding during
targeted therapy for advanced renal cell
carcinoma: a case report
Shintaro Fujihara1*, Hirohito Mori1, Hideki Kobara1, Takehiro Suenaga2, Yuji Hayashida2, Mikio Sugimoto2,
Yoshiyuki Kakehi2 and Tsutomu Masaki1Abstract
Background: Temsirolimus has important clinical activity in both untreated and previously treated patients with
advanced renal cell carcinoma. Targeted therapy–related stomatitis and mucositis have occurred during targeted
therapies, but there is no consensus on which strategy is the most effective. We herein report a case in which
several sessions of endoscopic hemostasis with argon plasma coagulation (APC) effectively resolved life-threatening
gastrointestinal bleeding that had occurred during targeted therapy. This is the first case report of such an adverse
drug reaction in the literature.
Case presentation: A 47-year-old female patient with advanced renal cell carcinoma was treated with
temsirolimus. Eight weeks after starting targeted therapy, the patient was admitted to our hospital for worsened
fatigue, pallor, and hematemesis. A complete blood count showed a marked drop in her hemoglobin level from
10.1 g/dl 4 days earlier to 2.9 g/dl. Esophagogastroduodenoscopy revealed diffuse mucosal bleeding of the antrum.
Endoscopy revealed diffuse reddish spots that resembled gastric antral vascular ectasia (GAVE) extending from the
pylorus into the antrum. One month after endoscopic hemostasis with APC and stopping temsirolimus, significant
improvement was shown in the gastric erythema and GAVE like lesions.
Conclusion: Minor hemorrhagic events are relatively common in patients treated with targeted agents. Life-
threatening hemorrhagic events are rarer than minor hemorrhagic complications. In the present case, endoscopic
hemostasis with APC effectively prevented severe anemia and blood loss due to gastrointestinal bleeding.
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With the advent of targeted agents for the treatment of
renal cell carcinoma (RCC), most patients are being
treated continuously for increasingly long periods of
time. This has raised new challenges related to manage-
ment of the associated adverse events [1].
Temsirolimus has important clinical activity in both un-
treated and previously treated patients with advanced RCC
[2]. Severe adverse events associated with temsirolimus are
uncommon; however, the most frequent grade 3 or 4* Correspondence: joshin@med.kagawa-u.ac.jp
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[3]. Targeted therapy–related stomatitis and mucositis have
occurred during targeted therapy, but there is no consen-
sus on which strategy is the most effective.
We herein report a case in which several sessions of
endoscopic hemostasis with argon plasma coagulation
(APC) effectively resolved life-threatening gastrointes-
tinal bleeding that had occurred during targeted therapy.Case presentation
The patient was a 40-year-old woman diagnosed as hav-
ing left renal cell carcinoma (cT3aN2M1) and adrenal
gland metastasis. She was surgically treatment, having
radical left nephrectomy in October 2009. There was nol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eases, liver cirrhosis and other disorders. The resected
tumor was pathologically diagnosed as collecting duct
carcinoma, G3 INFβ, v(+), ly(+) 7 cm pT2. In April 2010,
follow-up computerized tomography (CT) revealed
newly bronchial lymph node metastasis, and she re-
ceived initially 30 Gy radiation therapy for lymph node
metastasis to prevent bronchial stenosis. After the radi-
ation therapy, she complained of epigastralgia, so we
performed esophagogastroduodenoscopy (EGD). How-
ever it revealed no abnormality (Figure 1).
Temsirolimus (15 mg/day) was started in June 2012.
Her blood test results at various follow-ups showed mild
stable anemia (hemoglobin of 10.1–10.7 g/dl), but other
laboratory parameters were normal on all occasions, in-
cluding her chemistry panel and liver function tests.
Eight weeks after starting targeted therapy, the patient
was admitted to the Department of Gastroenterology for
worsening fatigue, pallor, and hematemesis. A complete
blood count showed a marked drop in her hemoglobin
level from 10.1 g/dl 4 days earlier to 2.9 g/dl. Her pro-
thrombin time and activated partial thrombin time were
normal. She had made no dosage changes to any of her
medications, and had not started/stopped any medica-
tion during targeted therapy.
EGD revealed diffuse mucosal bleeding of the antrum
(Figure 2A). Endoscopy showed diffuse reddish spots
that resembled gastric antral vascular ectasia (GAVE)
extending from the pylorus into the antrum. High-
resolution magnifying endoscopy (ME) revealed that the
mucosa was friable, and oozing bleeding occurred from
ectatic vessel rupture (Figure 2B). In the background
mucosa, brownish subepithelial capillaries were clearly
visualized by ME with narrow-band imaging, andFigure 1 Previous esophagogastroduodenoscopy before
starting targeted therapy.congestive and dilated subepithelial capillaries were
seen in the background mucosa (Figure 2C). These
findings represented a major change from the EGD
performed before targeted therapy. Pathologic examin-
ation revealed interstitial fibrosis and extensive edema
with capillary and venous dilatation in the submucosa
extending into the mucosa.
This complication was most likely an adverse reaction
to temsirolimus, because the patient had no underlying
medical conditions associated with GAVE and had no
evidence of GAVE on EGD before starting temsirolimus.
Treatment with a proton-pump inhibitor was started,
and follow-up with repeat endoscopic hemostasis with
argon plasma coagulation (APC) was performed once to
twice weekly (Additional file 1). The patient required
four to six units of packed red blood cells every day, and
the need for blood transfusion gradually decreased with
the hemostasis treatment. After three sessions of APC,
the patient did not need the blood transfusions, and the
improvement of GAVE like lesions.
Overall, the patient required a total of four sessions of
endoscopic hemostasis and 38 units of transfused blood
for severe anemia during these 2 weeks.
Four weeks after discontinuing temsirolimus, the
patient’s symptoms resolved and she was discharged in
good clinical condition 60 days after hospital admission.
One month after hospital discharge, significant improve-
ment was seen in the gastric erythema and GAVE like
lesions (Figure 3).
Discussion
Six targeted agents for the treatment of advanced RCC
are now approved and in clinical use: the tyrosine kinase
inhibitors sunitinib and pazopanib, the multikinase inhibi-
tor sorafenib, the anti–vascular endothelial growth factor
monoclonal antibody bevacizumab, and the mammalian
target of rapamycin (mTOR) inhibitors temsirolimus and
everolimus [1].
Temsirolimus is an inhibitor of mTOR kinase, a com-
ponent of intracellular signaling pathways involved in
the growth and proliferation of cells [4,5] and the re-
sponse of such cells to hypoxic stress [6]. The inhibition
of angiogenesis by temsirolimus is clinically relevant be-
cause unregulated angiogenesis is prominent in RCC [7].
Minor hemorrhagic events are relatively common in
patients treated with targeted agents; the most common
event reported in patients treated with bevacizumab,
sunitinib, temsirolimus, and everolimus is epistaxis,
which usually resolves without medical attention. Life-
threatening hemorrhagic events are rarer than minor
hemorrhagic complications. In the case of bevacizumab,
serious hemorrhage appears to be more frequently asso-
ciated with specific tumor types, such as non–small cell
lung cancer or cancer of the gastrointestinal tract [8].
Figure 2 Esophagogastroduodenoscopy (EGD) when the patient presented with gastrointestinal bleeding. (A) Esophagogastroduodenoscopy
revealed diffuse mucosal bleeding of the antrum that resembled gastric antral vascular ectasia. (B) Magnifying endoscopy (ME) findings. The
gastric mucosa was friable, and oozing bleeding occurred from ectatic vessel rupture. (C) ME with narrow-band imaging revealed congestive and
dilated subepithelial capillaries in the background mucosa.
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cause of upper gastrointestinal bleeding that is often con-
fused with portal hypertensive gastropathy, both of which
can occur in patients with cirrhosis [9]. A clear relation-
ship between mTOR inhibitors and the pathogenesis ofFigure 3 Esophagogastroduodenoscopy showed resolution of
the patient’s gastric antral vascular ectasia 1 month after
stopping temsirolimus, but diffuse angiodysplasia at the
antrum was present.targeted therapy-related stomatitis and GAVE has not
been shown. In one case, a patient with gastrointestinal
stromal tumors showed GAVE 8 months after starting
imatinib [10]. Recently, a paper by Kim et al. [11] pro-
vided information on the activation of mTOR signaling
pathways that promote wound healing in the stomach.
Inhibitors of mTOR kinase may affect mucosal healing
in the stomach and trigger gastritis and gastrointestinal
bleeding.
Endoscopic therapy remains the treatment of choice
for GAVE. Photocoagulation using a neodymium: yt-
trium-aluminum-garnet laser and APC have been suc-
cessful in treating GAVE and abolishing or reducing
transfusion requirements [12,13]. In the present case,
several sessions of endoscopic hemostasis with APC ef-
fectively prevented severe anemia and blood loss due to
gastrointestinal bleeding.
Conclusion
Minor hemorrhagic events are relatively common in
patients treated with targeted agents. Targeted therapy-
related stomatitis and mucositis have occurred during
targeted therapies, but there is no consensus on which
strategy is the most effective. mTOR inhibitors may be re-
lated to the development of stomatitis, mucositis, and vas-
cular ectasia through mTOR pathways. In the present case,
endoscopic hemostasis with APC effectively prevented
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case report of such an adverse drug reaction in the
literature.
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